Elegibility for Sacubitril/Valsartan in italian clinical practice: insights from the OPTIMA-HF registry

31 August 2024 (09:00 - 09:40)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Professor Stefania Paolillo

University of Naples Federico II, Naples (Italy)

7 More presentations in this session

Presentation thumbnail

Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry

Doctor S. Paolillo (Naples, IT)

Abstract Slides

Presentation thumbnail

Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i

Professor S. Tadic (Novi Sad, RS)

Abstract Slides

Presentation thumbnail

Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study

Doctor N. Okuda (Kawagoe, JP)

Abstract Slides

Presentation thumbnail

Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up

Doctor S. Varga (Sisak, HR)

Abstract Slides

Presentation thumbnail

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

Mrs O. Obertynska (Vinnitsa, UA)

Abstract Slides

Access the full session

Session thumbnail

Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

The Event

Event poster

ESC Congress 2024

31 August 2024 09:00 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Webinar

MRAs in heart failure: what's old is new again

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources